---
title: CDMOs offering Process Development with Cell Therapy
path: /explore/process-development/cell-therapy
companies_count: 37
---

# CDMOs offering Process Development with Cell Therapy

37 published CDMOs match Process Development and Cell Therapy.

Locations in this set include United States, United Kingdom, Japan, China, Denmark, and Australia.

Capabilities that show up most often in this set: CMC Analytical Development, Cell Therapy Manufacturing, Technology Transfer, Cell-Line Development, and Quality Control Testing.

## Matching companies

- [AGC Biologics](/companies/agcbio)
  - Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- [Akron Bio](/companies/akronbiotech)
  - Akron Bio manufactures cGMP-compliant recombinant proteins, media, buffers, and transfection reagents for cell and gene therapy companies. Services span process development, fill-finish, and custom ancillary product manufacturing.
- [Aldevron](/companies/aldevron)
  - Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
- [Andelyn Biosciences](/companies/andelynbio)
  - CDMO specializing in plasmid DNA and AAV viral vector manufacturing for cell and gene therapy, with digital-first platform emphasizing data integrity and collaboration.
- [Artis BioSolutions](/companies/artis-biosolutions)
  - Integrated CDMO platform combining proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing for mRNA, gene editing, viral vectors, cell therapies, and vaccines.
- [Asimov](/companies/asimov)
  - Asimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.
- [Boston Institute of Biotechnology, LLC](/companies/bostonbib)
  - Full-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.
- [Bramble Bio](/companies/bramble-bio)
  - Bramble Bio specializes in cGMP manufacturing and process development for cell therapy ATIMPs, including autologous and allogeneic therapies, with 20+ years of expertise, 16 Grade B cleanrooms, and support for over 8,000 dosed patients across 46 countries.
- [CDMO Network](/companies/cdmonetwork)
  - CDMO Network is a biomanufacturing partner-routing platform that connects biotech sponsors with specialized CDMO partners across modalities, development stages, and geographies to reduce integration friction and accelerate program execution.
- [Catalent](/companies/catalent)
  - Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
- [Cell Therapies](/companies/celltherapies)
  - GMP contract manufacturer of autologous and allogeneic cell therapies from first-in-human trials through commercial supply, with two decades of experience in CAR-T, mesenchymal stromal cells, TILs, and pluripotent stem cell derivatives. Offers end-to-end cold chain management, process development, quality control analytics, and regulatory consulting across Australia and Asia-Pacific.
- [Cell and Gene Therapy Catapult](/companies/ct)
  - UK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
- [Cell-Easy](/companies/cell-easy)
  - Cell-Easy is a CDMO specializing in development and GMP manufacturing of cell therapies, with expertise across T cells, NK cells, MSCs, and iPSCs. The company has manufactured over 1,000 clinical doses and supports 50+ development programs from process optimization through regulatory compliance.
- [Cellab CDMO](/companies/cellab)
  - Cell and gene therapy CDMO providing cell banking, GMP manufacturing, cryopreservation and EU QP batch release for clinical-stage ATMPs. Operates a 1,000 m² facility with four Grade B and one Grade C cleanroom plus an AABB-accredited cell bank.
- [Cellares](/companies/cellares)
  - Cellares operates a global network of Smart Factories delivering integrated development and manufacturing (IDMO) services for cell therapies, with proprietary Cell Shuttle® and Cell Q™ platforms enabling cGMP-compliant, automated manufacturing and quality control at clinical and commercial scale.
- [Cellipont Bioservices](/companies/cellipont-bioservices)
  - Cellipont Bioservices is a cell therapy CDMO offering end-to-end development, analytical, and cGMP manufacturing services for autologous, allogeneic, CAR-T, and iPSC-derived therapies from preclinical through commercial stages.
- [Cellistic](/companies/cellistic)
  - Cellistic is an iPSC-focused CDMO offering integrated cell line development, process development, and GMP manufacturing for allogeneic cell therapy and regenerative medicine programs. The company operates a purpose-built, EMA-certified and FDA/PMDA-compliant manufacturing facility in Belgium.
- [Celularity](/companies/celularity)
  - Celularity is a clinical and commercial-stage biotechnology company specializing in off-the-shelf placental-derived allogeneic cell therapies and advanced biomaterial products.
- [Charles River Laboratories](/companies/criver)
  - Charles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
- [Dr. Reddy's Laboratories](/companies/drreddys)
  - Integrated global pharmaceutical company manufacturing generics, APIs, biosimilars, and innovative medicines across 66 countries with capabilities in small molecule and biologics development and manufacturing.
